Sept 14 (Reuters) - Auscann Group Holdings Ltd AC8.AX :
* PHASE I PHARMACOKINETIC & SAFETY STUDY OF CO'S HARD-SHELL CAPSULES, USING NEUVIS PLATFORM, ACHIEVED ALL ENDPOINTS
* INVESTIGATOR-LED PHASE IIA STUDY OF CO'S PRODUCT IN PATIENTS WITH CHRONIC NEUROPATHIC PAIN IS EXPECTED TO COMMENCE IN Q2 FY2021